Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has issued an update.
Hemogenyx Pharmaceuticals has announced the first administration of its proprietary CAR-T cell therapy, HG-CT-1, to treat relapsed or refractory acute myeloid leukemia in adults. This milestone represents significant progress in their clinical development program, aiming to provide a life-saving treatment for AML patients with limited options, strengthening the company’s position in the biopharmaceutical industry.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded company headquartered in London with subsidiaries in New York City. It is a clinical-stage biopharmaceutical group focused on developing new medicines and treatments for blood and autoimmune diseases, aiming to expand the reach of bone marrow transplantation for otherwise incurable life-threatening diseases. The company is developing multiple product candidates and utilizes a platform technology for novel product development.
YTD Price Performance: -21.60%
Average Trading Volume: 19,569
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £11.44M
For an in-depth examination of HEMO stock, go to TipRanks’ Stock Analysis page.